In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Align Tech (ALGN – Research Report) yesterday and set a price target of ...

Quest Diagnostics (NYSE:DGX – Get Free Report) was upgraded by Leerink Partnrs from a “hold” rating to a “strong-buy” rating ...

Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has filed for a $100M initial public offering.  Read more here.

Mizuho has recently initiated DENTSPLY SIRONA Inc (XRAY) stock to Neutral rating, as announced on December 4, 2024, according to Finviz. Earlier, on November 7, 2024, Leerink Partners had reduced the ...